Extensively Drug-Resistant Tuberculosis clinical trials
The registry lists 23 studies for Extensively Drug-Resistant Tuberculosis across more than 10 countries. 1 are recruiting or about to start. 9 of them are mainly about Extensively Drug-Resistant Tuberculosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Extensively Drug-Resistant Tuberculosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Global Alliance for TB Drug Development (4) · Medecins Sans Frontieres, Netherlands (3) · Lisichansk Regional Tuberculosis Dispensary (2) · Médecins Sans Frontières, France (1) · Centers for Disease Control and Prevention (1) · Wits Health Consortium (Pty) Ltd (1) · University of Cape Town (1)
What is being tested here
Drugs under test in Extensively Drug-Resistant Tuberculosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Who these studies take
Of the 1 Extensively Drug-Resistant Tuberculosis studies recruiting now, 0 (0%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (100%) | 1 (100%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 23 studies, recruiting or not: 35% stop at 75 or younger and 22% at 65; 35% take children; 0% are for women only and 4% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 23 of 23. search them.
- Training Protocol on the Natural History of TuberculosisRecruitingNCT012120031 country
- TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TBCompletedNCT00664313Phase 1/21 country
- A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TBCompletedNCT02333799Phase 31 country
- Triage Test for All Oral DR-TB Regimen (TRiAD Study)CompletedNCT051757943 countries
- Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)CompletedNCT03896685Phase 36 countries
- A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary TuberculosisCompletedNCT04179500Phase 22 countries
- Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of CareCompletedNCT04062201Phase 31 country
- Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of PretomanidCompletedNCT04309656Phase 11 country
- Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)CompletedNCT02589782Phase 2/33 countries
- Economic Evaluation of New MDR TB RegimensCompletedNCT04207112Phase 2/33 countries
- Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant TuberculosisCompletedNCT03086486Phase 34 countries
- A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)CompletedNCT00685360Phase 29 countries
- An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant TuberculosisCompletedNCT02454205Phase 2/31 country
- PRACTECAL-PKPD Sub StudyStatus unknownNCT04081077Phase 2/32 countries
- Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, IndiaCompletedNCT043425981 country
- Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169CompletedNCT04150224Phase 11 country
- Tuberculosis in ChinaCompletedNCT010716031 country
- Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in MaliTerminatedNCT013817572 countries
- Linezolid to Treat Extensively-Drug Resistant TuberculosisCompletedNCT00727844Phase 21 country
- Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIVCompletedNCT01061593Phase 32 countries
- Global Consortium for Drug-resistant Tuberculosis DiagnosticsCompletedNCT021704413 countries
- Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis PatientsCompletedNCT01521364Phase 41 country
- Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV PatientsCompletedNCT01222338Phase 21 country